Targeting the synovial engine: next-generation engineered immune cells to eradicate pathogenic FLS in rheumatoid arthritis, with safety-first, selective designs - Summary - MDSpire
Advertisement
Targeting the synovial engine: next-generation engineered immune cells to eradicate pathogenic FLS in rheumatoid arthritis, with safety-first, selective designs
To discuss CAR-based immune cell therapies targeting fibroblast-like synoviocytes (FLS) in rheumatoid arthritis (RA) with a focus on safety and selectivity.
Approach:
Targeting Pathogenic FLS: The review discusses engineered immune cells (CAR-T, CAR-NK, CAR-macrophages) that target FLS-specific antigens, aiming to eliminate or modulate pathogenic FLS.
Safety-First Roadmap: A 'safety-first' translational roadmap is proposed, incorporating features such as transient CAR expression, safety switches, hypoxia-responsive constructs, and localized delivery.
Key Findings:
Current RA therapies yield low rates of full remission, with many patients experiencing residual synovitis.
Pathogenic FLS are key mediators of RA, showing hyperproliferation and resistance to apoptosis.
Direct targeting of FLS could address limitations of existing therapies and has shown promise in preclinical trials.
Interpretation:
Targeting pathogenic FLS with engineered immune cells could reshape RA treatment by dismantling the inflammation process with precision.
Limitations:
Existing therapies largely ignore stromal drivers of RA.
Clinical translation requires careful validation of targets and patient selection.
Conclusion:
The review advocates for innovative CAR-based therapies targeting FLS to improve RA treatment outcomes while prioritizing safety.
Nearly 40% of registry patients would have been excluded from phase 3 randomized controlled trials, with exclusion criteria distributed unevenly across drug classes.
The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.
